Catalog No.
PAB94402
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Infliximab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Remicade.
Specificity
The product is specific for Infliximab. This antibody serves as an excellent positive control for Infliximab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 170277-31-3
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Infliximab with the brand name of Remicade, is a chimeric monoclonal IgG1 antibody. It binds to TNF-α, which is a key proinflammatory cytokine involved in chronic inflammatory diseases. Infliximab functions as TNF-α blocker to disrupt the interaction of TNF-α with its receptors.
Drug survival, long-term safety and efficacy of anti-TNF-alpha biosimilars: a monocentric retrospective study., PMID:40485573
Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction., PMID:40484132
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data., PMID:40481399
Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature., PMID:40481366
Pharmacogenomics of TNF inhibitors., PMID:40469293
Peripheral neuropathies associated with anti-tnf-α treatments: a systematic review and proposed recommendations., PMID:40447953
Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials., PMID:40418343
Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis., PMID:40414945
Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis., PMID:40407729
Effects of infliximab infusion on clinical symptom scores and serum cytokines in patients with inflammatory bowel disease., PMID:40400059
Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis., PMID:40378993
Infliximab may contribute to remit rapidly progressive of IgA nephropathy secondary to Crohn's disease: A case report., PMID:40371441
SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy., PMID:40369811
Effect of additional intravenous immunoglobulin for infliximab-refractory Kawasaki disease: a cohort study., PMID:40361172
Clinician management of patients with Crohn's-related perianal fistulas: results of a multispecialty case-based survey., PMID:40350167
Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab., PMID:40341590
Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease-A Systematic Review., PMID:40338684
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis., PMID:40327280
Successful infliximab therapy in systemic sarcoidosis presenting with giant leg ulcers: a case based review., PMID:40327105
Compatibility between Proteins and Polysaccharide Excipients in Oral Delivery Tablets., PMID:40323221
Prevalence of opportunistic infections in Syrian inflammatory bowel disease patients on biologic therapy: a multi-center retrospective cross-sectional study., PMID:40320559
Expanding the clinical utility of reporter gene assay to infliximab biosimilars., PMID:40320158
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU., PMID:40317957
Granulocyte and Monocyte Adsorptive Apheresis Maintenance Therapy Restored the Loss of Response to Anti-TNF-Alpha Agents in the Patients With UC: A Case Report., PMID:40313140
Varicella Development after Infliximab Therapy for Refractory Pouchitis in Post-surgical Ulcerative Colitis., PMID:40307038
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies., PMID:40300779
Case 340., PMID:40298599
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial., PMID:40297751
IgA Nephropathy Associated With Infliximab Treatment in Patients With Crohn's Disease: Study of IgA1 and IgA2 Expression in Glomeruli., PMID:40295023
Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti-Drug Antibodies During Maintenance Therapy., PMID:40289444
Vitamin D enhances the therapeutic effect of TNF-α antibodies through lipid metabolism in overweight IBD patients., PMID:40285831
Measurement of Anti-TNF Biologics in Serum Samples of Pediatric Patients: Comparison of Enzyme-Linked Immunosorbent Assay (ELISA) with a Rapid and Automated Fluorescence-Based Lateral Flow Immunoassay., PMID:40284416
Relapsed refractory immune checkpoint inhibitor-induced colitis treated with tacrolimus and maintained with vedolizumab., PMID:40279047
Development and laboratory validation of an electrochemiluminescence ELISA technique for measuring infliximab concentrations and anti-drug antibodies., PMID:40268228
Pediatric Case of Crohn Disease, Immunoglobulin A Nephropathy, and Atopic Dermatitis., PMID:40258603
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study., PMID:40254990
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)., PMID:40243842
A real-world, observational, prospective cohort study evaluating the safety and effectiveness of CT-P13 in inflammatory bowel disease and rheumatoid arthritis: the MEGA-J study., PMID:40241664
Discovery of a deuterated TNF-α small molecule modulator for potential treatment of ulcerative colitis., PMID:40239485
[Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis]., PMID:40237750
Effects of biological agents on lipid profile and hemogram parameters in patients with psoriasis., PMID:40208364
Narrative review of adalimumab for the treatment of cardiac sarcoidosis., PMID:40201681
Adenosine-generating CD39+ plasmablasts predispose to successful infliximab therapy in pediatric IBD., PMID:40199584
Rapid, Single-Step Monitoring of Monoclonal Antibody Bioavailability by Using a TNF-α-Based Multiepitope DNA Nanoswitch., PMID:40198205
Medical management of acute severe ulcerative colitis in the hospitalized patient., PMID:40187895
The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring., PMID:40181987
Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model., PMID:40181734
Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report., PMID:40181234
Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn's disease., PMID:40169633
For research use only. Not for human or drug use.
